Core Insights - Eli Lilly and Company announced positive results from the TOGETHER-PsA Phase 3b clinical trial, demonstrating that the combination of Taltz and Zepbound significantly improved disease activity and patient-reported outcomes compared to Taltz monotherapy [1] Group 1: Clinical Trial Results - The TOGETHER-PsA trial evaluated the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with active psoriatic arthritis and obesity or overweight, along with at least one additional weight-related comorbidity [1] - Results were presented at the 2026 American Academy of Dermatology Annual Meeting and published in Arthritis & Rheumatology, indicating the effectiveness of the combination therapy [1]

Core Insights - Eli Lilly and Company is recognized as one of Goldman Sachs's top growth stock picks, particularly due to its promising clinical trial results and strategic licensing agreements [1]. Group 1: Clinical Trial Results - Eli Lilly announced that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) demonstrated superior efficacy compared to Taltz alone in treating adults with moderate-to-severe plaque psoriasis who are also overweight or obese [1]. - The Phase 3b TOGETHER-PsO study involved 274 adults, evenly divided between the treatment groups, with all participants receiving dietary advice and physical activity guidance. The study participants exhibited a high disease burden [2]. - Side effects in the combination treatment group were reported to be generally mild to moderate, consistent with existing knowledge about each medication [2]. Group 2: Licensing Agreement - On February 18, Eli Lilly entered into an exclusive licensing agreement with CSL Limited for clazakizumab, an anti-interleukin-6 monoclonal antibody, with Lilly responsible for development and commercialization in the licensed indications [3]. - CSL will retain rights for clazakizumab in preventing cardiovascular events in patients with end-stage kidney disease [3]. - The agreement includes an upfront payment of $100 million from Eli Lilly to CSL, along with potential milestone payments and royalties based on global net sales [4]. Group 3: Company Overview - Eli Lilly is a pharmaceutical manufacturer that develops treatments across various therapeutic areas, including diabetes, oncology, immunology, and neuroscience [4].

Group 1: Company Performance and Developments - Eli Lilly and Company (NYSE: LLY) is recognized as a strong long-term growth stock, with Jefferies reaffirming a Buy rating and setting a price target of $1,300.00 following positive trial results for its drugs Taltz and Zepbound [1] - The TOGETHER-PsA study demonstrated that the combination of Taltz and Zepbound achieved a primary endpoint of 50% improvement in psoriatic arthritis activity and a weight drop of ≥10%, outperforming Taltz monotherapy [2] - Eli Lilly announced the acquisition of Ventyx Biosciences, a clinical-stage biopharmaceutical company, for $14.00 per share, totaling an equity value of approximately $1.2 billion [3][4] Group 2: Drug Efficacy and Market Position - The combination of Taltz and Zepbound resulted in a 64% relative increase in patients achieving ACR50 compared to Taltz alone, marking Taltz as the first biologic with comprehensive treatment data for psoriatic arthritis [2] - Eli Lilly is actively securing its position in the obesity drug market, leveraging the efficacy of its products to enhance its competitive edge [2]

Core Insights - Oruka Therapeutics is developing ORKA-002, a novel monoclonal antibody with an extended half-life targeting IL-17A/F, which shows potential for less frequent dosing compared to existing therapies [1][3][6] - The half-life of ORKA-002 in non-human primates (NHP) exceeds 30 days, which is over three times longer than bimekizumab, suggesting a dosing interval of two to three times per year [1][6] - ORKA-002 demonstrates equivalent potency to bimekizumab with similar binding affinity, indicating a promising profile for treating chronic skin diseases like plaque psoriasis and psoriatic arthritis [2][3][6] Company Overview - Oruka Therapeutics aims to set a new standard for treating chronic skin diseases, focusing on achieving high rates of complete disease clearance with infrequent dosing [4] - The company is advancing a proprietary portfolio of antibodies engineered to target the core mechanisms of plaque psoriasis and other dermatologic conditions [4] Product Details - ORKA-002 is administered subcutaneously and has shown superior efficacy in preclinical studies compared to existing therapies that require monthly maintenance dosing [3][6] - Projections indicate that ORKA-002 could have a human half-life of approximately 50 to 75 days, allowing for dosing intervals of once every four months or twice a year [6]